Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents
| Autor: | Jong-Hoon Lee, M. Miles Braun, Sharon K. Gershon, Nancy R. Slifman, Evelyne T. Edwards |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
musculoskeletal diseases
Adult Male medicine.medical_specialty Adolescent Opportunistic infection medicine.medical_treatment Immunology Arthritis Gastroenterology Receptors Tumor Necrosis Factor Etanercept Arthritis Rheumatoid Psoriatic arthritis Rheumatology Internal medicine medicine Immunology and Allergy Adverse Drug Reaction Reporting Systems Humans Pharmacology (medical) Listeriosis Adverse effect Aged business.industry Tumor Necrosis Factor-alpha Antibodies Monoclonal Immunosuppression Middle Aged medicine.disease Infliximab Rheumatoid arthritis Antirheumatic Agents Immunoglobulin G Female business medicine.drug |
| Zdroj: | Arthritis and rheumatism. 48(2) |
| ISSN: | 0004-3591 |
| Popis: | Objective Tumor necrosis factor α (TNFα) has been implicated in the pathogenesis of certain inflammatory diseases. Two TNFα-neutralizing agents are licensed in the US. Infliximab is licensed for the treatment of Crohn's disease (CD) and, when used with methotrexate, for the treatment of rheumatoid arthritis (RA). Etanercept is licensed for the treatment of RA, including juvenile RA, and, more recently, was licensed for the treatment of psoriatic arthritis. Because of the potential for decreased host resistance to infectious agents due to treatment with anti-TNFα agents, we sought to evaluate postlicensure cases of opportunistic infection, including Listeria monocytogenes, in patients treated with these products. Methods The FDA Adverse Event Reporting System, a passive monitoring system, was reviewed to identify all reports of adverse events (through December 2001) associated with L monocytogenes infection in patients treated with infliximab or etanercept. Results Fifteen cases of L monocytogenes infection associated with infliximab or etanercept treatment were identified. In 14 of these cases, patients had received infliximab. The median age of all patients was 69.5 years (range 17–80 years); 53% were female. Six deaths were reported. Among patients for whom an indication for use was reported, there were 9 patients (64%) with RA and 5 patients (36%) with CD (information was not reported for 1 patient). All patients for whom information was reported were receiving concurrent immunosuppressant drugs. Conclusion Postlicensure surveillance suggests that L monocytogenes infection may be a serious complication of treatment with TNFα-neutralizing agents, particularly infliximab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text